Melissa Mclaughlin Sells 1,624 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insider Melissa Mclaughlin sold 1,624 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $319.59, for a total value of $519,014.16. Following the transaction, the insider directly owned 11,729 shares in the company, valued at approximately $3,748,471.11. This represents a 12.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Melissa Mclaughlin also recently made the following trade(s):

• On Monday, April 6th, Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $330.42, for a total value of $755,340.12.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $327.25 on Thursday. The company has a market cap of $43.40 billion, a P/E ratio of 191.37 and a beta of 0.39. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The business’s 50 day moving average price is $325.00 and its 200-day moving average price is $392.52. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.65) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently made changes to their positions in ALNY. Root Financial Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $27,000. HM Payson & Co. purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $27,000. Finally, Golden State Wealth Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ALNY shares. Jefferies Financial Group reissued a “hold” rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research report on Friday, January 30th. Needham & Company LLC cut their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Finally, Leerink Partners cut their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $473.87.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: New cardiovascular data highlights upside for Alnylam’s programs in ATTR‑CM and hypertension, suggesting a bigger commercial opportunity beyond its current liver‑targeted RNAi launches — this clinical readout is the main near‑term bullish catalyst investors are citing. Read More.
• Neutral Sentiment: Insider sales by Melissa McLaughlin (1,624 and 2,286 shares sold in early April) have been reported; the filings show the trades were done under a pre‑arranged Rule 10b5‑1 plan and were used to cover tax withholding on vested awards — activity worth roughly $1.27M in aggregate but described as routine by the filings. Read More. Read More.
• Neutral Sentiment: Options flow is showing elevated activity and positioning that some market commentators interpret as traders betting on an upcoming spike or higher volatility in ALNY — this can amplify intraday moves but is ambiguous on direction. Read More.
• Negative Sentiment: Alnylam’s most recent quarterly report (Feb. 12) missed EPS and revenue estimates (EPS $1.25 vs. $1.43 expected; revenue $1.10B vs. $1.16B expected), and some analysts still model a weak near‑term EPS profile — that earnings backdrop remains a headwind for valuation until sustained revenue/earnings outperformance is confirmed. Read More.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.